Anti-GTPase HRAS Antibody (FITC)
|Name:||Anti-GTPase HRAS Antibody (FITC)|
|Description:||Rabbit polyclonal antibody to GTPase HRAS (FITC)|
|Applications:||ELISA, IP, WB|
|Dilutions:||ELISA: 1:10,000; ELISA: 1:10,000; Immunoprecipitation: 1:150; Western Blot: 1:500|
|Reactivity:||Chicken, Human, Mouse|
|Immunogen:||Synthetic peptide taken within amino acid region 100-150 on human GTPase HRAS protein.|
|Concentration:||1.00-1.25 µg/µl in antibody stabilization buffer|
|Storage:||-20⁰C for long term storage|
|Function:||Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.|
|Tissue Specificity:||Widely expressed.|
|Involvement in Disease:||Costello syndrome: A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
Congenital myopathy with excess of muscle spindles: Variant of Costello syndrome.
Thyroid cancer, non-medullary, 2: A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.
Bladder cancer: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
Schimmelpenning-Feuerstein-Mims syndrome: A disease characterized by sebaceous nevi, often on the face, associated with variable ipsilateral abnormalities of the central nervous system, ocular anomalies, and skeletal defects. Many oral manifestations have been reported, not only including hypoplastic and malformed teeth, and mucosal papillomatosis, but also ankyloglossia, hemihyperplastic tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi follow the lines of Blaschko and these can continue as linear intraoral lesions, as in mucosal papillomatosis.
|Sequence Similarities:||Belongs to the small GTPase superfamily. Ras family.|
|Post-Translational Modification:||Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.|
|Cellular Location:||Cell membrane. Cell membrane. Golgi apparatus. Golgi apparatus membrane.
The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
|Synonyms:||C BAS/HAS Antibody
c H ras Antibody
C HA RAS1 Antibody
c has/bas p21 protein Antibody
c ras Ki 2 activated oncogene Antibody
GTP and GDP binding peptide B Antibody
GTPase HRas, N-terminally processed Antibody
GTPase KRas Antibody
GTPase NRas Antibody
H Ras 1 Antibody
H RASIDX Antibody
Ha Ras Antibody
Ha Ras1 proto oncoprotein Antibody
Harvey rat sarcoma viral oncogene homolog Antibody
Harvey rat sarcoma viral oncoprotein Antibody
K ras Antibody
K RAS2A Antibody
K RAS2B Antibody
K RAS4A Antibody
K RAS4B Antibody
N ras Antibody
N-terminally processed Antibody
p19 H RasIDX protein Antibody
Ras family small GTP binding protein H Ras Antibody
Transformation gene oncogene HAMSV Antibody
Transforming protein p21 Antibody
v Ha ras Harvey rat sarcoma viral oncogene homolog Antibody
v Ki ras2 Kirsten rat sarcoma viral oncogene homolog Antibody
v ras neuroblastoma RAS viral oncogene homolog Antibody
VH Ras Antibody
vHa RAS Antibody
|Information:||Target information shown above is from the UniProt Consortium.|